Q2 2026 · Form 13F LedgerData source: SEC EDGAR  
H

HOLDER.TOP

Who owns what — the quarterly ledger of U.S. institutional holdings.
EN · 简 · 繁
Funds / Exome Asset Management LLC
Form 13F · Q2 2026

Exome Asset Management LLC

CIK 2011932Filed 2026-08-1413F-HR View the filing on EDGAR ↗
$162M
Reported book value
52
Positions
11
Quarters on record
Top 50
Positions

Exome Asset Management LLC — holdings

Top 50 positions of 52, ranked by reported value. Share change is versus the previous quarter.
#SecuritySharesShare Δ QoQValue% of book
1GH Guardant Health Inc67,500−18.4%$10M6.2%
2PRAX Praxis Precision Medicines I27,205−40.2%$9M5.6%
3TGTX Tg Therapeutics Inc164,915—$9M5.6%
4COGT Cogent Biosciences Inc210,523−24.4%$8M5.0%
5IONS Ionis Pharmaceuticals Inc88,177−19.9%$7M4.3%
6LLY Eli Lilly & Co5,492−21.7%$7M4.1%
7ABIVAX SA Abivax Sa46,878—$6M3.9%
8ALMS Alumis Inc204,418−26.8%$6M3.5%
9CYTK Cytokinetics Inc60,056−42.1%$5M3.2%
10ELVN Enliven Therapeutics Inc100,203−54.5%$5M3.1%
11VERA Vera Therapeutics Inc97,276−15.4%$4M2.6%
12UNH Unitedhealth Group Inc9,612−25.3%$4M2.5%
13TXG 10X Genomics Inc102,629−33.4%$4M2.4%
14NTRA Natera Inc13,800−26.0%$4M2.3%
15UNIQURE NV Uniqure Nv81,056—$4M2.3%
16RYTM Rhythm Pharmaceuticals Inc32,209−20.6%$4M2.2%
17MAZE Maze Therapeutics Inc114,692+29.6%$3M2.1%
18GLUE Monte Rosa Therapeutics Inc137,115−23.6%$3M2.0%
19MLTX Moonlake Immunotherapeutics166,493−22.7%$3M2.0%
20ALKS Alkermes Plc61,336−27.1%$3M2.0%
21LQDA Liquidia Corporation39,224−14.4%$3M1.9%
22UTHR United Therapeutics Corp Del5,410−23.3%$3M1.8%
23GKOS Glaukos Corp19,862−4.8%$3M1.7%
24ARWR Arrowhead Pharmaceuticals In32,214−29.5%$3M1.6%
25AGIO Agios Pharmaceuticals Inc70,500−43.6%$3M1.6%
26CBIO Crescent Biopharma Inc.127,769−16.6%$2M1.4%
27AZN Astrazeneca Plc12,045—$2M1.4%
28BSX Boston Scientific Corp48,347+0.0%$2M1.3%
29ADAG Adagene Inc488,293−33.7%$2M1.3%
30PEN Penumbra Inc6,300+0.0%$2M1.2%
31ISRG Intuitive Surgical Inc4,908−22.8%$2M1.2%
32VKTX Viking Therapeutics Inc47,861—$2M1.2%
33OCUL Ocular Therapeutix Inc181,588—$2M1.1%
34EQ Equillium Inc552,956—$2M1.1%
35ASND Ascendis Pharma A/S6,573—$2M1.1%
36CRBP Corbus Pharmaceuticals Hldgs184,914−21.0%$2M1.1%
37CTMX Cytomx Therapeutics Inc.460,067−11.8%$2M1.1%
38VSTM Verastem Inc429,041−32.6%$2M1.0%
39NKTR Nektar Therapeutics22,417—$2M1.0%
40CLPT Clearpoint Neuro Inc83,636—$1M0.9%
41INSM Insmed Inc13,873−47.9%$1M0.9%
42CAI Caris Life Sciences Inc78,180—$1M0.9%
43BBIO Bridgebio Pharma Inc18,359−72.8%$1M0.8%
44ZBIO Zenas Biopharma Inc52,443−35.0%$1M0.8%
45NBP Novabridge Biosciences576,960+0.0%$1M0.7%
46ESTA Establishment Labs Hldgs Inc13,100+0.0%$1M0.7%
47RLAY Relay Therapeutics Inc47,531−82.9%$889,3050.5%
48GERN Geron Corp624,046—$798,7790.5%
49DRUG Bright Minds Biosciences Inc10,110—$709,7220.4%
50CMPX Compass Therapeutics Inc276,165—$604,8010.4%
Source: Form 13F filings via SEC EDGAR. Positions as of Jun 30, 2026. Options (put/call) are excluded from share counts.